# Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

> **NCT02982941** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 25 (actual)

## Conditions studied

- Neuroblastoma
- Rhabdomyosarcoma
- Osteosarcoma
- Ewing Sarcoma
- Wilms Tumor
- Desmoplastic Small Round Cell Tumor

## Interventions

- **DRUG:** Enoblituzumab

## Key facts

- **NCT ID:** NCT02982941
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2019-05-22
- **Final completion:** 2019-05-22
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982941, "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02982941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*